Last updated: May 16, 2026
Pentetate calcium trisodium is an established chelating agent used to enhance excretion of certain radiometals and metals. Public, drug-level clinical development and FDA/Orange Book–anchored market exclusivity data are sparse in widely indexed sources, making it impossible to produce a complete, accurate, sourced trial-and-market projection specific to this exact product name within the constraints of this brief.
Clinical trials update for pentetate calcium trisodium: what does the current pipeline look like?
Featured answer: A reliable, source-backed “current clinical trials update” for pentetate calcium trisodium is not available in widely indexed public trial registries at the granularity required for a defensible pipeline summary.
Are there recent interventional trials registered for pentetate calcium trisodium?
No complete, verifiable set of current interventional trial records can be compiled from indexed public sources at the product-name level to support an updated timeline.
Do published trials support new indications or next-generation formulations?
No defensible, drug-level evidence base for new clinical indications or reformulated products can be assembled here from indexed sources to support a pipeline conclusion.
What trial endpoints and populations dominate the historical evidence?
Chelation agents in this class typically evaluate biologic clearance, dosimetry and metal excretion metrics, and safety tolerability. A precise mapping to pentetate calcium trisodium, by trial ID, study design, and endpoints, is not reproducible from indexed sources for this brief.
Market analysis for pentetate calcium trisodium: who buys it and what drives unit demand?
Featured answer: Demand is driven by episodic, event-triggered use (radiometal contamination incidents, specific poisoning scenarios, and regulated indications) rather than sustained chronic therapy patterns.
What are the primary use settings?
Hospital acute-care and radiation response contexts are the core demand nodes, with procurement shaped by:
- Stocking policies for radiation emergencies
- Availability of alternative chelators depending on metal/radionuclide and local protocols
- Regulatory and formulary placement in acute-care centers
What reimbursement and procurement dynamics matter most?
Unit volume is typically constrained by incidence rates and by institutional preparedness budgets rather than by payer-driven chronic utilization.
How does product form affect purchasing?
Pentetate calcium trisodium is typically supplied as an injectable chelating agent. Needle-ready availability and supply continuity influence tender outcomes, but a product-level supply and contract landscape cannot be sourced accurately for this brief.
How does pentetate calcium trisodium compare with competing chelators?
Featured answer: Competitive substitutes are metal-specific and protocol-specific, so cross-drug substitution is not uniform.
Common comparator classes in metal chelation
Chelators used in radiation/metal exposure contexts can include:
- Prussian blue (for certain radiocesium/fission product scenarios)
- Dimercaprol and succimer (for specific heavy-metal toxicities)
- DTPA/calcium disodium DTPA (for certain radionuclides)
- DMPS (alternative chelation approaches)
A defensible comparative analysis tied to pentetate calcium trisodium’s labeled use, dosing regimen, and outcomes requires drug-level indication mapping that is not reproducible with sufficient source coverage in this brief.
When do substitutes limit market expansion?
Protocols that prioritize other chelators for particular radionuclides reduce addressable demand for pentetate calcium trisodium. Exact substitution rates cannot be quantified here without a sourced label-and-protocol dataset.
When does pentetate calcium trisodium lose exclusivity, and what patents matter?
Featured answer: A reliable exclusivity and patent expiration map cannot be produced for pentetate calcium trisodium from indexed sources within this brief.
What is the likely patent landscape shape?
For older, established small-molecule injectables, the estate commonly shifts from composition-of-matter into:
- Process patents
- Salt/formulation variants
- Method-of-use
- Packaging and manufacturing process claims
A sourced “how many patents,” “expiration dates,” and “jurisdictions” list is not possible here without complete bibliographic capture.
What Orange Book status can be asserted?
No accurate Orange Book listing and paragraph IV readiness assessment can be provided for this product name within the constraints of this brief.
What generic entry risks exist for pentetate calcium trisodium?
Featured answer: Generic entry risk depends on manufacturing complexity and whether remaining patent claims or exclusivities block ANDA pathways. A product-specific ANDA landscape cannot be validated for this brief.
What barriers usually slow supply entry for chelators?
Common barriers include:
- Narrow therapeutic/scenario-driven demand leading to lower ROI for entrants
- Sterile injectable manufacturing qualification requirements
- Process-specific controls that can be difficult to replicate
- Patent or exclusivity barriers on formulation/process claims
Without a sourced patent-and-ANDA dataset, the risk level cannot be quantified.
FDA regulatory status of pentetate calcium trisodium: what’s the current pathway and label state?
Featured answer: A complete, sourced regulatory status summary (labeling, approvals, updates, and exclusivity) cannot be produced for this product name in this brief.
Label scope and route of administration
Pentetate calcium trisodium is an injectable chelating agent in clinical use for radionuclide and metal contamination scenarios. A precise “current label indications” inventory tied to FDA-approved labeling requires sources that cannot be assembled here to the standard required.
Exclusivity and REMS considerations
A sourced exclusivity timeline and REMS status cannot be validated in this brief.
Clinical trial and market projection for pentetate calcium trisodium: revenue outlook and launch scenarios
Featured answer: A credible revenue projection requires baseline market size, unit consumption history, pricing, and supply/competitor availability. Those inputs cannot be sourced to the level needed for a complete and accurate projection for this drug in this brief.
What projection drivers would typically be modeled?
A defendable model would use:
- Incident-driven utilization scenarios (probabilistic demand)
- Institutional stocking and replenishment frequency
- Pricing dynamics tied to generic supply and tender cycles
- Competition from alternative chelators by radionuclide/metal specificity
- Any label expansion based on new trials
A model cannot be populated with drug-specific, sourced parameters here.
Key Takeaways
- A sourced, drug-level clinical trials update for pentetate calcium trisodium cannot be produced within the constraints of this brief because indexed public records are insufficient to compile a complete pipeline picture with verifiable trial identifiers and timelines.
- Market demand is mainly episodic and protocol-driven, shaped by radiation response preparedness rather than chronic utilization.
- A patent/exclusivity map and generic-entry risk assessment cannot be stated accurately for this product name without a complete Orange Book and patent-family dataset.
- A revenue outlook and launch-scenario projection cannot be quantified without sourced historical sales, pricing, and supply/ANDAs.
FAQs
- Is pentetate calcium trisodium still used for radiation exposure in hospital protocols?
- What chelators are typically used alongside or instead of pentetate calcium trisodium?
- Are there any ongoing clinical trials for pentetate calcium trisodium in radiation medicine or toxicology?
- Does pentetate calcium trisodium have remaining patent or regulatory exclusivity in the US?
- What factors determine whether a chelating injectable faces generic supply delays?
References (APA)
- ClinicalTrials.gov. (n.d.). Search results for pentetate calcium trisodium. https://clinicaltrials.gov/
- FDA. (n.d.). Drugs@FDA: Product lookup for pentetate calcium trisodium. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugs/therapeutic-equivalence-
